US2019056405A1PendingUtilityA1
Amplifying rare cell surface markers
Assignee: MASSACHUSETTS GEN HOSPITALPriority: Mar 12, 2010Filed: Aug 17, 2018Published: Feb 21, 2019
Est. expiryMar 12, 2030(~3.6 yrs left)· nominal 20-yr term from priority
G01N 33/5759G01N 2333/705G01N 2458/10G01N 15/1484G01N 2015/149G01N 33/57492C12Q 1/6804G01N 2015/0065G01N 15/01G01N 15/149
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates generally to a microfluidic device for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell.
Claims
exact text as granted — not AI-modified1 - 8 . (canceled)
9 . A system for detecting expression of a specific protein or peptide by individual cells of a population of cells, the system comprising:
a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; rolling circle amplification reagents for detection of the presence of the specific protein or peptide; and a device operable to detect the rolling circle amplification reagents in individual subsamples.
10 . The system of claim 9 , wherein the rolling circle amplification reagents comprise a phi29 DNA polymerase or a circular DNA template or both.
11 . The system of claim 9 , wherein the rolling circle amplification reagents comprise a biotinylated antibody that binds specifically to the protein or peptide, an avidin bridge, a biotinylated DNA probe, and a circular DNA template capable of hybridizing with the biotinylated DNA probe.
12 . The system of claim 11 , wherein the rolling circle amplification reagents further comprise a phi29 polymerase and a fluorescently-labeled nucleotide.
13 . The system of claim 11 , wherein the biotinylated antibody binds specifically to a protein or peptide expressed by a cancer cell, a stem cell, or an immune cell.
14 . The system of claim 11 , wherein the biotinylated antibody binds specifically to an epithelial cell adhesion molecule (EpCAM).
15 . The system of claim 9 , further comprising a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample.
16 . The system of claim 15 , wherein the cell sorting mechanism comprises a fluorescence activated cell sorting mechanism.
17 . The system of claim 9 , wherein dividing the sample into subsamples comprises combining aqueous sample fluid from a first inlet channel with a hydrophobic carrier fluid.
18 . A kit comprising:
a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; and rolling circle amplification reagents for detection of the presence of the specific protein or peptide.
19 . The kit of claim 18 , wherein the rolling circle amplification reagents comprise a phi29 DNA polymerase or a circular DNA template or both.
20 . The kit of claim 18 , wherein the rolling circle amplification reagents comprise a biotinylated antibody that binds specifically to the protein or peptide, an avidin bridge, a biotinylated DNA probe, and a circular DNA template capable of hybridizing with the biotinylated DNA probe.
21 . The kit of claim 20 , wherein the rolling circle amplification reagents further comprise a phi29 polymerase and a fluorescently-labeled nucleotide.
22 . The kit of claim 20 , wherein the biotinylated antibody binds specifically to a protein or peptide expressed by a cancer cell, a stem cell, or an immune cell.
23 . The kit of claim 20 , wherein the biotinylated antibody binds specifically to an epithelial cell adhesion molecule (EpCAM).Join the waitlist — get patent alerts
Track US2019056405A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.